Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 192% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 4.9% — below-average profitability
- Revenue growing at 44% annually
ANI PHARMACEUTICALS, INC. (ANIP) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $1.7 billion . Key value metrics: P/E ratio 62.3, P/B ratio 3.07, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
ANI PHARMACEUTICALS, INC. — Fundamental Analysis Summary
ANI PHARMACEUTICALS, INC. (ANIP) is currently trading 192% above its Graham Number of $25.33, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 62.3x.
On financial health, ANIP shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 4.9% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.54.
StockPik's composite Value Score for ANIP is 59/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ANIP reports a solid gross margin of 58.2% (sector average: 33.5%) and a modest operating margin of 7.1%.
ANIP shows revenue growing at 44% year-over-year, with earnings growing at 523%.